26 September 2017 12:00 BST
�
TRANSACTION BY PERSON DISCHARGING MANAGERIAL RESPONSIBILITIES
Disclosure under Article 19 of the EU Market Abuse Regulation
�
AstraZeneca PLC (the Company) announces that, on 25 September 2017, an award of the Company's American Depositary Shares (ADSs) made under the AstraZeneca Restricted Share Plan (AZRSP) vested to Sean Bohen, a person discharging managerial responsibilities (PDMR) of the Company. Two ADSs are equivalent to one Ordinary Share of $0.25 in the Company.
�
The AZRSP award was granted on 25 September 2015 and vested in two tranches on the first and second anniversaries of grant. Following the withholding of shares to satisfy certain tax obligations arising on vesting, Mr Bohen became beneficially entitled to and received 12,385 ADSs.
�
For tax purposes, the fair market value of an ADS at vest was $33.95, being the closing price on the last trading day preceding the vesting day.
�
Further details are set out in the attached notification, made in accordance with the requirements of the EU Market Abuse Regulation.
�
�
About AstraZeneca
AstraZeneca is a global, science-led biopharmaceutical company that focuses on the discovery, development and commercialisation of prescription medicines, primarily for the treatment of diseases in three therapy areas - Oncology, Cardiovascular & M etabolic Diseases and Respiratory. The Company also is selectively active in the areas of autoimmunity, neuroscience and infection. AstraZeneca operates in over 100 countries and its innovative medicines are used by millions of patients worldwide.
�
For more information, please visit www.astrazeneca.com and follow us on Twitter @AstraZeneca.
�
|
Media Relations |
|
|
|
Esra Erkal-Paler |
UK/Global |
+44 203 749 5638 |
|
Karen Birmingham |
UK/Global |
+44 203 749 5634 |
|
Rob Skelding |
UK/Global |
+44 203 749 5821 |
|
Matt Kent |
UK/Global |
+44 203 749 5906 |
|
Jacob Lund |
Sweden |
+46 8�553�260 20 |
|
Michele Meixell |
US |
+1 302 885 2677 |
|
|
|
|
|
Investor Relations |
|
|
|
Thomas Kudsk Larsen |
� � |
+44 203 749 5712 |
|
Craig Marks |
Finance, Fixed Income, M&A |
+44 7881 615 764 |
|
Henry Wheeler |
Oncology |
+44 203 749 5797 |
|
Mitchell Chan |
Oncology |
+1 240 477 3771 |
|
Christer Gruvris |
Diabetes; Autoimmunity, Neuroscience & Infection |
+44 203 749 5711 |
|
Nick Stone |
Respiratory; Brilinta |
+44 203 749 5716 |
|
US toll free |
|
+1 866 381 7277 |
Adrian Kemp
Company Secretary, AstraZeneca PLC
|
1
|
Details of the person discharging managerial responsibilities / person closely associated |
|||||
|
a)
|
Name |
Sean Bohen |
||||
|
2
|
Reason for the notification
|
|||||
|
a)
|
Position/status
|
Person discharging managerial responsibilities |
||||
|
b)
|
Initial notification /Amendment |
Initial notification |
||||
|
3
|
Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor |
|||||
|
a)
|
Name |
AstraZeneca PLC |
||||
|
b)
|
LEI |
PY6ZZQWO2IZFZC3IOL08 |
||||
|
4i
|
Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transactions have been conducted |
|||||
|
a)
|
Description of the financial instrument, type of instrument
Identification code
|
AstraZeneca PLC American Depositary Shares
CUSIP: 046353108 |
||||
|
b)
|
Nature of the transaction
|
Acquisition of ADSs pursuant to vesting under the AstraZeneca Restricted Share Plan, for nil consideration. |
||||
|
c)
|
Price(s) and volume(s)
|
|
||||
|
d)
|
Aggregated information
- Aggregated volume - Price
|
Not applicable - single transaction |
||||
|
e)
|
Date of the transaction
|
25 September 2017 |
||||
|
f)
|
Place of the transaction
|
Outside a trading venue |
||||